<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02745496</url>
  </required_header>
  <id_info>
    <org_study_id>MULTIPROS Study</org_study_id>
    <nct_id>NCT02745496</nct_id>
  </id_info>
  <brief_title>Advanced Magnetic Resonance Imaging (MRI) in Men With Suspected Prostate Cancer</brief_title>
  <acronym>MULTIPROS</acronym>
  <official_title>Multiparametric Magnetic Resonance Imaging Characterization and Guided Biopsy of the Prostate in Men Suspected of Having Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Dundee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NHS Tayside</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Prostate Cancer UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tayside Clinical Trials Unit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Health Informatics Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chief Scientist Office of the Scottish Government</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Dundee</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical trial aims to address the critical challenge of differentiating aggressive from&#xD;
      indolent prostate cancers by correlating prospectively collected MultiParametric (MP)&#xD;
      Magnetic Resonance Imaging (MRI) data (index test) with the histopathology of radical&#xD;
      prostatectomy specimens (reference standard).&#xD;
&#xD;
      The study design incorporates pre-biopsy MRI, routine standard of care Transrectal Ultrasound&#xD;
      guided (TRUS) biopsies and MRI/Ultrasound (US) image fusion techniques to guide biopsies to&#xD;
      the suspicious areas identified by MRI.&#xD;
&#xD;
      The hypothesis is that MP-MRI will allow pre-treatment determination of prostate cancer&#xD;
      aggressiveness and MRI/US image fusion is expected to accurately co-locate cancer foci within&#xD;
      the prostate gland for guiding biopsies.&#xD;
&#xD;
      Pre-treatment prediction of Gleason grade as a marker of cancer aggressiveness will better&#xD;
      inform clinicians and patients to improve risk stratification and facilitate decision making&#xD;
      on subsequent treatment.&#xD;
&#xD;
      Image fusion will allow accurate targeting of the most suspicious areas on MP-MRI for biopsy,&#xD;
      which could obviate the need for multiple biopsies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is preliminary evidence suggesting that MultiParametric Magnetic Resonance Imaging&#xD;
      (MP-MRI) can be a marker for prostate cancer (PCa) aggressiveness and could be used to plan&#xD;
      treatment. Gleason grade (GG) is a critical predictor of the aggressiveness of PCa, but in up&#xD;
      to one in three men, the histology of radical prostatectomy specimens is different from the&#xD;
      histology of Transrectal Ultrasound (TRUS)-guided biopsies. This discrepancy contributes to-&#xD;
      and is a sign of- poor risk stratification of men with localised PCa.&#xD;
&#xD;
      The research aims to answer the following questions:&#xD;
&#xD;
        1. Can image-fusion techniques allow investigators to reliably target abnormal areas seen&#xD;
           on MP-MRI?&#xD;
&#xD;
        2. How reliable is pre-biopsy MP-MRI in correctly predicting aggressive disease?&#xD;
&#xD;
      The investigators envisage that MP-MRI information will reduce unnecessary biopsies and&#xD;
      over-detection of indolent PCa, while improving the detection of aggressive disease.&#xD;
&#xD;
      Primary Objectives&#xD;
&#xD;
      • To determine whether using MP-MRI can improve cancer detection and characterization of&#xD;
      prostate cancer&#xD;
&#xD;
      Secondary Objectives&#xD;
&#xD;
      • To determine whether US/MRI FUSION guided biopsy can reduce the number of false negative&#xD;
      biopsies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Actual">December 2020</completion_date>
  <primary_completion_date type="Actual">August 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of prostate cancers detected by MP-MRI when compared to gold standard prostatectomy specimen</measure>
    <time_frame>5 years from first recruitment</time_frame>
    <description>Number of prostate cancers detected by MP-MRI when compared to gold standard</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of clinically significant cancers detected by MP-MRI when compared to gold standard prostatectomy specimen</measure>
    <time_frame>5 years from first recruitment</time_frame>
    <description>The definition of clinically significant disease will be based on the pathologic assessment of radical prostatectomy (RP) specimen and will include the presence of any the following three prognostic factors:&#xD;
o Gleason grade &gt;= 7 with pattern 4 or/and 5 Maximum cancer focus size more than 6mm measured in the axial plane Presence of extracapsular extension (ECE)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of cancer detected in each randomised group, namely intervention group (TRUS/FUSION biopsy) versus standard of care (TRUS biopsy)</measure>
    <time_frame>5 years from first recruitment</time_frame>
    <description>Number of cancer detected in each randomised group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of significant cancer detected in each randomised group, namely intervention group (TRUS/FUSION biopsy) versus standard of care (TRUS biopsy)</measure>
    <time_frame>5 years from first recruitment</time_frame>
    <description>Number of significant cancer detected in each randomised group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety outcomes(death, post biopsy pain, bleeding, sepsis and hospitalization) of intervention (biopsy) in each of the two randomised groups.</measure>
    <time_frame>4 years from first recruitment</time_frame>
    <description>Number of participants with deaths, side effects (post biopsy pain, bleeding, sepsis and hospitalization) in each of the two randomised groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of MRI negative standard of care TRUS guided biopsies with MRI positive TRUS histopathology to facilitate analysis of diagnostic accuracy of MRI in men suspected with target condition.</measure>
    <time_frame>5 years from first recruitment</time_frame>
    <description>Comparison of MRI negative standard of care TRUS guided biopsies with MRI positive TRUS histopathology</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">603</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>TRUS Biopsy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard of Care Treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TRUS/FUSION Biopsy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Interventional Treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TRUS Biopsy</intervention_name>
    <description>Standard of Care Treatment</description>
    <arm_group_label>TRUS Biopsy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TRUS/FUSION Biopsy</intervention_name>
    <description>Interventional Treatment</description>
    <arm_group_label>TRUS/FUSION Biopsy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males between the age of 40-75 at referral&#xD;
&#xD;
          -  With at least 10 years life expectancy&#xD;
&#xD;
          -  With clinically localised PCa: Prostate Specific Antigen (PSA) ≤20 ng/ml&#xD;
&#xD;
          -  And/or abnormal Digital Rectal Examination (DRE) but &lt; T3 disease&#xD;
&#xD;
          -  Ability to informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to give informed consent&#xD;
&#xD;
          -  Prior prostatic biopsy within 12 months&#xD;
&#xD;
          -  Contraindications to biopsy&#xD;
&#xD;
          -  Poor general health and life expectancy &lt; 10 years&#xD;
&#xD;
          -  Previous diagnosis of acute prostatitis within 12 months&#xD;
&#xD;
          -  History of prostate cancer&#xD;
&#xD;
          -  Prior transurethral prostatectomy&#xD;
&#xD;
          -  Contraindications to MRI (cardiac pacemakers, allergic reaction to gadolinium based&#xD;
             contrast, renal function with baseline eGRF 30 ml/min, intracranial clips,&#xD;
             claustrophobia)&#xD;
&#xD;
          -  Previous hip replacement&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ghulam Nabi</last_name>
    <role>Study Director</role>
    <affiliation>University of Dundee</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ninewells Hospital and Medical School</name>
      <address>
        <city>Dundee</city>
        <state>Tayside</state>
        <zip>DD5 4NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 4, 2016</study_first_submitted>
  <study_first_submitted_qc>April 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2016</study_first_posted>
  <last_update_submitted>June 24, 2021</last_update_submitted>
  <last_update_submitted_qc>June 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Dundee</investigator_affiliation>
    <investigator_full_name>Ghulam Nabi</investigator_full_name>
    <investigator_title>Professor in Surgical Uro-oncology</investigator_title>
  </responsible_party>
  <keyword>Image-guided biopsy</keyword>
  <keyword>Tumour detection</keyword>
  <keyword>Diagnostic</keyword>
  <keyword>Biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

